INTRODUCTION
============

Misfolded and orphan polypeptides in the endoplasmic reticulum (ER) of eukaryotic cells are detected and dispatched to the cytosol for proteasomal elimination via ER quality control pathways known collectively as ER-associated degradation (ERAD). Usually, they are extracted from the ER membrane by a p97/Cdc48p complex ([@B8]; [@B73]; [@B35]; [@B52]; [@B54]; [@B22]), polyubiquitylated by membrane-bound dislocation complexes ([@B15]; [@B19]), and degraded by 26S proteasomes. Although a large number of components required for ERAD in yeast and mammalian cells has now been identified for a range of substrates ([@B49]; [@B50]), it is not clear whether a given cell will handle different forms of the same soluble substrate in exactly the same way.

To investigate this, we have used the protein cytotoxin ricin. Native holotoxin normally traffics to the ER lumen of target mammalian cells ([@B62]) where it becomes reduced to its cell-binding B chain (RTB) and a structurally native cytotoxic A chain (RTA; [@B10]; [@B63]). RTA is then thought to masquerade as a misfolded protein in order to co-opt an unknown number of ERAD components ([@B69]; [@B44]). Subsequently, RTA is dislocated to the cytosol where it depurinates 28S rRNA, inhibiting protein synthesis ([@B23]). A dearth of lysyl residues in RTA ([@B31]; [@B18]) reduces polyubiquitylation potential, presumably hampering targeting to proteasomes. Cytosolic RTA then disengages from ERAD, refolding to a catalytic conformation, assisted by Hsc70 ([@B61]). These observations led us to probe the requirements for uncoupling from ERAD by comparing native RTA with a structurally defective form (RTA~Δ~; [@B59]), which is known to be a model glycosylated, ubiquitylated ERAD substrate whose fate depends on the Png1p--Rad23p complex that acts between Cdc48p and the proteasome ([@B39]).

The extreme sensitivity of mammalian cells to ricin makes identification of the ERAD components exploited by this toxin very difficult. Because there are many similarities between yeast and mammalian ERAD ([@B38]) and because yeast ribosomes are less sensitive to RTA toxicity than their mammalian counterparts, we expressed these RTA variants in the yeast ER lumen by targeting the nascent proteins with a Kar2 signal peptide. Using biochemical analyses with both toxin forms and survival assays with native RTA, we identified a requirement for cycling via the Golgi complex and for the Hrd1p-Hrd3p ERAD dislocation complex. Although these precytosolic requirements are similar for both toxins, we unexpectedly find that the Cdc48p and proteasome requirements are strikingly different, demonstrating that structural features of an ERAD substrate can influence its ultimate fate.

MATERIALS AND METHODS
=====================

Yeast Strains and Plasmids
--------------------------

A yeast gene knockout collection derived from strain BY4741 (MATa *his*Δ1, *leu2*Δ0, *met15*Δ0, *ura3*Δ0) was sourced from Open Biosystems (Huntsville, AL; [Table 1](#T1){ref-type="table"}). Other strains used are also listed in [Table 1](#T1){ref-type="table"}. Cultures were grown in rich YPDA media or synthetic media containing standard ingredients and 2% glucose (SD medium), 2% raffinose (SR medium), or 2% raffinose + 2% galactose (SRG medium). Where appropriate, medium lacking uracil and leucine was utilized. Yeast transformations were achieved by using the lithium acetate/single-stranded DNA/polyethylene glycol method as previously described ([@B27]).

###### 

Yeast strains used in this study

  Strain        Genotype                                                                                                                             Source/Reference
  ------------- ------------------------------------------------------------------------------------------------------------------------------------ ------------------
  BY4741        MATa *his*Δ*1*, *leu2*Δ*0*, *met15*Δ*0*, *ura3*Δ*0*                                                                                  Open Biosystems
  *cdc48-1*     *cdc48-1, prc1-1, ura3-52, ade2-101, lys2-801, can1-100*                                                                             [@B73]
  *cdc48-3*     *cdc48-3, prc1-1, leu2-3,-112, ura3-52, ade2-101*                                                                                    [@B73]
  SNY1025       MATα Δ*scj1::TRP1 ura3 leu2 trp1 his3 lys2 suc2*                                                                                     [@B32]
  SNY1028       MATα Δ*jem1::LEU2 ura3 leu2 trp1 his3 lys2 suc2*                                                                                     [@B32]
  SNY1026-7A    MATα Δ*jem1::LEU2* Δ*scj1::TRP1 ura3 leu2 trp1 his3 lys2 suc2*                                                                       [@B32]
  KRY167        *ade2-1 ura3-1 his3-11,15 leu2-3,112 trp1-1 can1-100 prc1-1 (pep4::URA3)*                                                            [@B28]
  JN284         MATα *ura3-52*, *leu2 (-3,-112)*, *his7-2*, *ise1*                                                                                   [@B24]; [@B68]
  YPH 499       MATa *ura3-52 leu2*-D*1 his3*-D*200, trp1*-D*63 lys2-801 ade2-101*                                                                   [@B26]
  CMY 763       MATa *cim3-1, ura3-52 leu2*-D*1 his3*-D*200*                                                                                         [@B26]
  CMY 765       MATa *cim5-1, ura3-52 leu2*-D*1 his3*-D*200*                                                                                         [@B26]
  DHY9          MATα *ura3-52 lys2-801 ade2-101 trp1*-Δ*1 his3*-Δ*200 leu2*-Δ*1*                                                                     [@B64]
  RSY188        DHY9, Δ*emp24::HIS* Δerv25*::HIS3* Δ*erp1::TRP1* Δ*erp2::HIS3* Δerp3*::loxP* Δerp4*::loxP* Δ*erp5::loxP* Δ*erp6::loxP-Kan^r^-loxP*   [@B64]
  RSY263        MATα *sec12-4 ura3-52*                                                                                                               [@B37]
  RSY281        MATα *sec23-1 ura3-52 his4-619*                                                                                                      [@B37]
  *SUB62*       MATa *his3*-Δ*200 lys2-801 leu2-3,112 trp1-1 ura3-52*                                                                                [@B55]
  *Rpt2RF*      MATa *his3*-Δ*200 lys2-801 leu2-3,112 trp1-1 ura3-52, rpt2RF*                                                                        [@B55]
  *Rpt4R*       MATa *his3*-Δ*200 lys2-801 leu2-3,112 trp1-1 ura3-52, rpt4R*                                                                         [@B55]
  Cl3-ABYS-86   MATα *pra1-1 prb1-1 prc1-1 cps1-3 ura3*Δ*5 leu2-3, 112 his*^−^                                                                       [@B33]
  *pre1-1*      Cl3-ABYS-86, *pre1-1*                                                                                                                [@B33]

Construction of ERAD Substrates and Phenotype Complementation
-------------------------------------------------------------

RTA~Δ~ is a misfolded protein in which a stretch of five amino acids from within the active site has been deleted. For screening yeast strains using a viability assay, RTA~E177A~ was used. This protein contains a minor active site change and exhibits only sixfold reduced activity ([@B40]). This slight attenuation of activity was a safeguard to permit survival should there be a less than full cotranslational coupling of ER import by the Kar2p signal peptide in situations where retrotranslocation was completely blocked. In experiments where RTA stability was measured, the less potent RTA~E177D~ was used ([@B16]; [@B3]). Structure determination has shown that this toxin shows only a subtle change within the active site cleft ([@B3]) and can therefore be regarded, like RTA~E177A~, as having an essentially native conformation. However, the protein has a 50--70-fold reduced catalytic activity ([@B16]), and this permits greater growth of yeast cells and easier visualization of toxin by SDS-PAGE. For simplicity, both RTA~E177A~ and RTA~E177D~ (essentially native) toxins are referred to as RTA throughout. PCR was used to fuse the yeast Kar2p signal sequence with the open reading frames of RTA~E177A~ ([@B40]) and RTA~E177D~ ([@B3]). Fusions were cloned under the transcriptional control of the *GAL1* promoter in a yeast expression vector derived from pRS316 ([@B57]). A fusion gene encoding Kar2-RTA~Δ~ with a deletion of five amino acids in the active site that renders it both inactive and misfolded ([@B59]) was similarly cloned downstream of the *GAL1* promoter. In addition, the open reading frame of RTA~E177D~ lacking a signal sequence was cloned downstream of the GAL1 promoter for cytosolic expression. RTA variants lacking lysyl residues---RTA~E177A~(1K) and RTA~E177A~(0K)---were created using a QuickChange II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). RTA~E177A~(1K) was constructed by changing Lys^239^ to Arg using the following oligonucleotides: 5′-gccgatgatatattccccagacaatacccaattataaac-3/5′-gtttataattgggatttgtctggggaatatatcatcggc-3′. RTA~E177A~(0K) was generated by changing Lys^4^ in RTA~E177A~(1K) to Arg using the oligonucleotides 5′-caaagacgtaatggttccagattcagtgtgtacgatgtg-3′/5′-cacatcgtacacactgaatctggaaccattacgtctttg-3′. Generation of a plasmid for the expression of a catalytically inactive Hrd1p involved altering Cys399 to Ser ([@B12]) and cloning both the wild-type and mutant versions in an integrating vector with a *LEU2* selective marker.

Pulse-Chase Analysis
--------------------

Yeast cells carrying plasmids that expressed Kar2p-RTA fusions under control of the *GAL1* promoter were grown overnight at 30°C in SR medium. Cells (1.48 × 10^8^) were harvested and washed before being incubated (30 min, 30°C) in inducing SRG medium lacking methionine. After addition of 280 μCi·ml^−1^ \[^35^S\]methionine/cysteine the cells were incubated (20 min, 30°C), after which excess unlabeled methionine and cysteine were added. Chase samples were taken at time zero and various time points thereafter (see figure legends). Metabolically labeled RTA was immunoprecipitated from cell lysates as described previously ([@B59]). Products were analyzed by reducing SDS-PAGE and autoradiography and were quantified using TotalLab software (Newcastle upon Tyne, United Kingdom). Where temperature-sensitive strains were used, cells were grown at the permissive temperature for growth and shifted to the restrictive temperature for 2 h before the start of the radioactive pulse. Where required, cells were incubated in medium containing inhibitors of protein trafficking (300 μM brefeldin A \[BFA\]), proteasomal degradation (20 μM clasto-lactacystin β-lactone \[cLβ-l\]) or *N*-glycosylation (25 μg·ml^−1^ tunicamycin) for 30 min before pulse-chase analysis, and the inhibitors were maintained throughout the pulse chase. To trap any ubiquitylated intermediates, expression of ER-targeted RTA or RTA~Δ~ was induced by growth in galactose medium for 2 h in the presence or absence of cLβ-l. Cells were then pulse-labeled for 20 min, and cell lysates were prepared as before but with the addition of 10 mM *N*-ethyl maleimide in the initial lysis buffer.

Growth Sensitivity to Ricin A Chain
-----------------------------------

Yeast cells expressing a fusion of the Kar2 signal peptide and RTA~E177A~ were grown overnight in liquid SR medium lacking uracil. Tenfold serial dilutions of cells from 10^6^ to 10^1^ were plated on *S*-galactose plates (2% galactose) lacking uracil to induce expression and on *S*-glucose plates (2% glucose) as controls. Plates were incubated at 30°C for 4 d and examined for growth differences.

RESULTS
=======

ER Import Is a Prerequisite for the Degradation of Ricin A Chain
----------------------------------------------------------------

Pulse-labeled ER-directed RTA~Δ~ has nonglycosylated (g0) and singly (g1), and doubly glycosylated (g2) forms: in contrast, ER-targeted RTA occurs primarily as g0 with a minor fraction of g1 ([Figure 1](#F1){ref-type="fig"}A), suggesting that ER-directed RTA folds rapidly ([@B2]). Both disappeared during a 1-h chase with unlabeled amino acids ([Figure 1](#F1){ref-type="fig"}B), not by turnover in vacuoles, nor by secretion, because disappearance was unaltered in a yeast strain lacking vacuolar proteinase A (Pep4p) that is required for activation of many vacuolar proteases ([Figure 1](#F1){ref-type="fig"}C), and both were absent from extracellular medium (not shown). In marked contrast, RTA expressed cytosolically remained stable ([Figure 1](#F1){ref-type="fig"}B) unlike a previously characterized cytosolic CPY\*-GFP fusion ([@B47]). Thus ER import is a prerequisite for RTA degradation.

![RTA is degraded after import into the ER lumen. Two RTA variants were immunoprecipitated from detergent soluble extracts prepared after a pulse of radiolabeled \[^35^S\]methionine/cysteine with or without a subsequent chase of unlabeled amino acids for the times indicated. Samples were analyzed by SDS-PAGE and fluorography, and fluorograms were quantified using TotalLab software. (A) Immunoprecipitated pulse-labeled RTA (lanes 3 and 4) and RTA~Δ~ (lanes 5 and 6). Lanes 1 and 2, in vitro--translated mature RTA (−SP) and Kar2p signal peptide-RTA fusion (+SP). g0, nonglycosylated; g1, singly glycosylated; g2, doubly glycosylated; Tn, tunicamycin; \*, unprocessed RTA. (B) Pulse-chase kinetics of ER-targeted RTA and cytosolic RTA. (C) Pulse-chase kinetics of the two ER-targeted RTAs in KRY167 (a *pep4* deletion strain).](zmk0151095250001){#F1}

Misfolded and Native RTAs Require the Hrd1-Hrd3p Complex for Dislocation
------------------------------------------------------------------------

RTA severely hampers yeast cell growth when expressed within the ER lumen in a form that is competent to acquire a native conformation after its retrotranslocation to the cytosol ([@B3]). This effect on viability is due to A chain--catalyzed depurination of the EF-2--binding site on the ribosome and the consequent inhibition of protein synthesis ([@B23]), even though most of the dislocated toxin is proteolysed in the cytosol ([@B59]). Two major membrane-associated E3 ubiquitin ligase complexes (Hrd1p--Hrd3p and Doa10p) play roles in ERAD dislocation ([@B15]; [@B19]). Open Biosystems yeast knockout strains with deletions of genes encoding proteins associated with these complexes were transformed with RTA and examined by viability assay on both noninducing (glucose) and inducing (galactose) plates ([Figure 2](#F2){ref-type="fig"}A, [Table 1](#T1){ref-type="table"}) and by monitoring RTA stability by pulse-chase analysis ([Figure 2](#F2){ref-type="fig"}B). Genetic deletions that conferred growth advantages correlated with acquired stability on pulse-chase. RTA~Δ~ was also stabilized in Δ*hrd1* but not in Δ*doa10* yeast strains ([Figure 2](#F2){ref-type="fig"}C), as shown in a previous study ([@B39]). The need for Hrd3p, Usa1p, and Der1p is consistent with the critical involvement of Hrd1p, because these cofactors form a near stoichiometric complex even though Der1p itself is only involved in the turnover of a subset of luminal (or ERAD-L) substrates ([@B41]; [@B65]; [@B34]; [@B15]). We also note relatively minor roles for Usa1p, which is required for optimal activity of the Hrd1-Hrd3 complex ([@B14]); the membrane-integral Cue1p, which recruits ([@B11]) and activates Ubc7p ([@B9]); and Ubx2p, which couples the Hrd1 complex to the cytosolic Cdc48 complex ([@B70]).

![RTA variants dislocate via the Hrd1p--Hrd3p--Der1p complex. (A) Viabilities of yeast strains harboring RTA were assessed by spotting dilutions of cells on noninducing (glucose, left) and inducing (galactose, right) media after growth at 30°C for 5 d. WT, wild-type BY4741. (B) Typical immunoprecipitates of pulse-chase samples revealed by SDS-PAGE/fluorography (gel slices). The associated mean quantitations (±1 SD) of native RTA in selected strains are presented graphically, where n = 4 (WT, Δ*hrd1*, Δ*hrd3*, Δ*ubx2,* and Δ*ubc7*), 3 (Δ*der1*), or 2 (Δ*usa1,* Δ*cue1,* and Δ*doa10*). Overlapping error bars have been omitted for clarity. (C) Pulse-chase analysis of RTA~Δ~ in WT (left, top), Δ*hrd1* (middle), and Δ*doa10* strains (bottom) and their quantitations (right, graph). In all cases quantitations reflect the sum of all RTA bands in each lane (graphs).](zmk0151095250002){#F2}

Retrotranslocation of Native RTA Does Not Depend on an Active Hrd1p or on Lysyl Ubiquitylation
----------------------------------------------------------------------------------------------

Because the Hrd1 complex is required, we examined the importance of the catalytic activity of this E3 ubiquitin ligase for RTA dislocation ([Figure 3](#F3){ref-type="fig"}). Expression of either wt Hrd1p or the catalytically inactive Hrd1~C399S~ ([@B12]) in a Δ*hrd1* strain restored the toxicity of RTA, resulting in an inhibition of growth ([Figure 3](#F3){ref-type="fig"}A). That Hrd1~C399S~ lacked catalytic activity was also confirmed by its ability to stabilize CPY\* ([Figure 3](#F3){ref-type="fig"}B). The dislocation of RTA must therefore require structural features of Hrd1p rather than its catalytic activity. We further show that dislocation of the native toxin does not involve ubiquitylation of lysyl residues because changing one or both endogenous lysines to arginine does not alter the requirement for Hrd1p ([Figure 3](#F3){ref-type="fig"}C). Eventual fate in the cytosol is also independent of canonical ubiquitylation because the turnover of native RTA is identical to that of RTA(0K) ([Figure 3](#F3){ref-type="fig"}D). We conclude that both RTA variants serve as ERAD-L substrates in a process that, for the native toxin, is independent of its lysine content and does not require the catalytic activity of Hrd1p.

![RTA dislocation and fate are not mediated by ubiquitylation of lysyl residues. (A) Top, viabilities of WT and Δh*rd1* strains expressing RTA on noninducing (glucose) and inducing (galactose) media. Lower panel: viabilities of WT and Δ*hrd1* strains expressing RTA after complementation, as appropriate, with wild type (WT) or catalytically inactive Ubc7p or Hrd1p on noninducing (glucose) and inducing (galactose) media. (B) Imunoprecipitates of pulse-chase samples of CPY\* in the Open BioSystems CPY knockout strain (PRC1) overexpressing either wild-type *HRD1* (top) or *Hrd3C399S* (middle), and associated quantitations (bottom, graph). (C) Viabilities of WT and the indicated mutant strains expressing RTA variants lacking one (RTA(1K)) or both (RTA(0K)) endogenous lysyl residues on noninducing (glucose) and inducing (galactose) media. (D) RTA fate is independent of lysine content. Typical immunoprecipitates of pulse-chase samples of RTA (top) and RTA(0K) (middle) and their quantitations (bottom, graph); n = 2.](zmk0151095250003){#F3}

Access to the Golgi Is Essential for Dislocation of Both Forms of RTA
---------------------------------------------------------------------

Active ER--Golgi transport is required for a number of yeast ERAD substrates ([@B13]; [@B66]; [@B30]; [@B67]). We therefore tested the effects of the fungal metabolite BFA that fuses endosomal compartments and merges the Golgi and ER, reversibly blocking early but not late protein transport steps in the yeast secretory pathway ([@B29]). In the drug-sensitive strain JN284 ([@B68]), BFA treatment stabilized both RTA and RTA~Δ~, compared with cells treated only with the BFA vehicle ethanol ([Figure 4](#F4){ref-type="fig"}A).

![RTA dislocation requires Golgi transport. (A) Pulse-chase kinetics of the indicated RTAs in the drug sensitive yeast strain JN284. Cells treated with solvent alone (top; EtOH, ethanol) and cells treated with 300 μM BFA dissolved in EtOH (middle) and their quantitations of the amount of immunoprecipitated RTA as measured by densitometry and expressed as a percentage of the total RTA present at the end of the pulse (bottom, graph). (B) Pulse-chase of RTA~Δ~ in a *sec12* mutant. Top, permissive temperature; bottom, restrictive temperature. (C) Pulse-labeled RTA (top) in *sec12* (middle) and *sec23* strains (bottom). (D) Top, viabilities of wild-type (WT) and Δ*erp2* cells expressing RTA on inducing medium (galactose); middle, viabilities of WT and Δ*erp2* strains expressing RTA after complementation, as appropriate, with vector or wt Erp2p on inducing (galactose-Ura-Leu); and bottom, viabilities of WT DHY9 and p24Δ8 yeasts expressing RTA on inducing (galactose) medium. (E) Pulse-chase of RTA in WT strain (top) and in Δ*erp2* (middle) and quantitations as described for A (bottom; n = 4 or 5 ±1 SD). (F) Pulse-chase of RTA~Δ~ in wild-type strain (top) and in Δ*erp2* cells (bottom).](zmk0151095250004){#F4}

ER-to-Golgi transport requires COPII vesicles. In a mutant containing a temperature-sensitive lesion in Sec12p, a guanine nucleotide exchange factor of the COPII-associated GTPase Sar1p ([@B7]), RTA~Δ~ was stabilized at the restrictive temperature (37°C, [Figure 4](#F4){ref-type="fig"}B), but not at the permissive temperature (24°C). Structurally native RTA was also stabilized at the restrictive temperature ([Figure 4](#F4){ref-type="fig"}C) but not at the permissive temperature (24°C, not shown). Likewise, in a strain bearing a temperature-sensitive lesion in Sec23p, a GTPase-activating protein that stimulates Sar1p ([@B21]), RTA was rendered stable at the restrictive temperature ([Figure 4](#F4){ref-type="fig"}C) but not at the permissive temperature (24°C, not shown).

Finally, for native RTA, we investigated the p24 mediators of ER-to-Golgi trafficking ([@B64]). A particularly striking growth advantage was seen in cells lacking Erp2p after induction of RTA expression ([Figure 4](#F4){ref-type="fig"}D, top). Individual deletion of each of the other p24 family members (*ERP1, ERP3-6, EMP24* and *ERV25*) and additional proteins localized to COPII-coated ER exit sites did not permit such survival ([Table 2](#T2){ref-type="table"}). Expression of functional Erp2p protein in the Δ*erp2* strain restored normal RTA toxicity ([Figure 4](#F4){ref-type="fig"}D, middle). Curiously, deletion of all eight p24 family genes gave only a slight growth advantage compared with the congenic parental strain ([Figure 4](#F4){ref-type="fig"}D, bottom). This is consistent with previous observations showing that individual p24 proteins act as negative regulators of COPII vesicle entry for different substrates ([@B64]). As expected, pulse-labeled RTA was stabilized in the Δ*erp2* strain ([Figure 4](#F4){ref-type="fig"}E), as indeed was RTA~Δ~, pointing to a common requirement for Erp2p function for both these substrates ([Figure 4](#F4){ref-type="fig"}F).

###### 

Growth characteristics of the gene deletion library members screened for survival after induced expression of ER--targeted RTA

  Gene deletion                           Growth advantage (fold)[^a^](#TF2-1){ref-type="table-fn"}   
  --------------------------------------- ----------------------------------------------------------- ---------
  Dislocation complex proteins                                                                        
      *CUE1*                              YMR264W                                                     10--100
      *UBC7*                              YMR022W                                                     10--100
      *HRD1*                              YOL013C                                                     ∼1000
      *DOA10*                             YIL030C                                                     nme
      *HRD3*                              YLR207W                                                     ∼1000
      *USA1*                              YML029W                                                     ∼100
      *DER1*                              YBR201W                                                     ∼1000
  ER-Golgi transport                                                                                  
      *ERP1*                              YAR002C-A                                                   nme
      *ERP2*                              YAL007C                                                     10,000
      *ERP3*                              YDL018C                                                     nme
      *ERP4*                              YOR016C                                                     nme
      *ERP5*                              YHR110W                                                     nme
      *ERP6*                              YGL002W                                                     nme
      *EMP24*                             YGL200C                                                     nme
      *ERV25*                             YML012W                                                     nme
      *ERV29*                             YGR284C                                                     nme
      *ERV41*                             YML067C                                                     nme
      *ERV46*                             YAL042W                                                     nme
      *ERV14*                             YGL054C                                                     nme
      *EMP46*                             YLR080W                                                     nme
      *EMP47*                             YFL048C                                                     nme
  ER luminal chaperones                                                                               
      *YOS9*                              YDR057W                                                     nme
      *MNL1*                              YHR204W                                                     nme
      *JEM1*                              YJL073W                                                     nme
      *CNE1*                              YAL058W                                                     nme
  Cytosolic chaperones and cochaperones                                                               
      *HLJ1*                              YMR161W                                                     nme
      *ZUO1*                              YGR285C                                                     nme
      *APJ1*                              YNL077W                                                     nme
      *YDJ1*                              YNL064C                                                     nme
      *SSA1*                              YAL005C                                                     nme
      *SSA2*                              YLL024C                                                     nme
      *SSA3*                              YBL075C                                                     nme
      *SSZ1*                              YHR064C                                                     nme
      *SSE1*                              YPL106C                                                     nme
      *SNL1*                              YIL016W                                                     nme
      *STI1*                              YOR027W                                                     nme
      *HSC82*                             YMR186W                                                     nme
      *HSP82*                             YPL240C                                                     nme
      *CPR6*                              YLR216C                                                     nme
      *CPR7*                              YJR032W                                                     nme
      *SBA1*                              YKL117W                                                     nme
      *AHA1*                              YDR214W                                                     nme
      *HCH1*                              YNL281W                                                     nme
  Proteasome and associated proteins                                                                  
      *UBR1*                              YGR184C                                                     nme
      *RPN10*                             YHR200W                                                     nme
      *SEM1*                              YDR363W-A                                                   nme
      *UBP6*                              YFR010W                                                     nme
      *UMP1*                              YBR173C                                                     nme
      *PNG1*                              YPL096W                                                     nme
      *RAD23*                             YEL037C                                                     nme
      *RAD4*                              YER162C                                                     nme
      *DSK2*                              YMR276W                                                     nme
  Cdc48p and its binding proteins                                                                     
      *NPL4*                              YBR170C                                                     nme
      DOA1                                YKL213C                                                     nme
      *OTU1*                              YFL044C                                                     nme
      *SHP1*                              YBL058W                                                     nme
      *UBX2*                              YML013W                                                     ∼10
  Signal peptidase complex                                                                            
      *SPC1*                              YJR010C-A                                                   nme
      *SPC2*                              YML055W                                                     nme

^a^ nme, no measurable effect.

Role of Luminal and Cytosolic Chaperones
----------------------------------------

ERAD of many misfolded proteins is aided by DnaJ domain--containing Hsp40 cochaperones that interact with the ER luminal chaperone Kar2p/BiP, improving their solubility in the ER lumen ([@B51]). One way of demonstrating indirectly any role of Kar2p in RTA retrotranslocation is to examine single and double knockouts of Kar2p-interacting Hsp40s, by viability testing. The single deletion Hsp40 Δ*jem1* mutant was as sensitive to RTA expression as wild-type cells ([Figure 2](#F2){ref-type="fig"}A, [Table 2](#T2){ref-type="table"}). However, upon extended growth (7 d), a Δ*scj1*Δ*jem1* double knockout showed slightly increased survival (not shown). This suggests that these Kar2p-interacting Hsp40s in conjunction are required for optimal toxicity, confirming similar findings for the viral A/B toxin K28 ([@B32]). In the context of Δ*jem1* this requirement was not obvious presumably because Scj1p could largely substitute for the other Hsp40. In a strain missing the lectin chaperone Yos9p ([Figure 2](#F2){ref-type="fig"}A), which also interacts with Kar2p ([@B19]), or Mnl1p, an ER mannosidase implicated in glycoprotein destruction ([Table 2](#T2){ref-type="table"}), RTA remained able to retrotranslocate, inhibiting protein synthesis and therefore cell growth to the same extent as observed in the congenic strain. We conclude that although RTA requires multiple Kar2p cochaperones for optimal retrotranslocation, it does not show an absolute requirement for proteins typically regarded as part of the ER glycoprotein surveillance machineries.

In principle, acquisition of a catalytic conformation by dislocated cytosolic RTA could be accomplished by substrate (ribosome)-mediated refolding ([@B4]), by spontaneous refolding ([@B53]) or by interactions with cytosolic components such as chaperones ([@B61]). Because chaperones can also provide routes to the proteasome ([@B5]), knockout of these proteins and/or their cochaperones might alter the sensitivity of the yeast cells expressing toxin. We therefore examined members of the gene knockout library lacking cytosolic chaperones or their cochaperones for survival after RTA expression. No clear growth advantage was seen for cells lacking individual Hsp40, Hsp70, and Hsp90 family members or Hsp70 and Hsp90 cochaperones ([Table 2](#T2){ref-type="table"}). However, as for ER chaperones, redundancy of cytosolic chaperones might obscure their roles when examined in the context of single knockouts.

Cdc48p Is Required for the ERAD of Misfolded RTA~Δ~ But Not for Native RTA
--------------------------------------------------------------------------

Cdc48p functions in a cofactor dependent manner in the recruitment of polyubiquitylated proteins that are destined for degradation. Because it acts between ubiquitylation and proteasomal degradation it is generally assumed that different ERAD pathways merge here ([@B73], [@B74]; [@B6]). Because loss of *CDC48* is lethal, we examined the stability of the RTA variants when expressed in conditional *cdc48* mutants: the cold-sensitive *cdc48-1* and the temperature-sensitive *cdc48-3* ([@B73]; [@B36]). Predictably, RTA~Δ~ showed a strong requirement for Cdc48p, being stabilized at 23°C in the cold-sensitive strain and at 37°C in the temperature-sensitive strain ([Figure 5](#F5){ref-type="fig"}A). However, no obvious Cdc48p dependence was seen in the case of native RTA ([Figure 5](#F5){ref-type="fig"}B). This surprising finding is in contrast to the Cdc48p requirement observed when RTA is retrotranslocated from the ER of tobacco cells ([@B45]). In plant cells, the ERAD pathway remains poorly defined although a number of plant-specific features have been recognized ([@B20]). We speculate that a Cdc48p requirement in plants may be needed in tissues where ribosome inactivating proteins are normally made in order to ensure a tighter coupling of extraction and degradation to prevent autointoxication of ribosomes. Tobacco leaves are known to express a RIP (termed TRIP; [@B56]).

![Cdc48p and its cofactor Npl4 are required for dislocation of misfolded RTA but not for native RTA. (A) Pulse-chase analyses at the restrictive temperatures of cold-sensitive *cdc48-1* and temperature-sensitive *cdc48-3* strains. Immunoprecipitates of misfolded RTA~Δ~ (A) or RTA (B) are shown. (A and B) Bottom panels, quantitations of the radiolabeled protein remaining at each time point and expressed as a percentage of the RTA present at the end of the pulse; n = 2 or 3; bars, ±1 SD. (C) Pulse-chase analysis of misfolded RTA~Δ~ and RTA in WT and in Δ*npl4*. Bottom panels, quantitations as described for A and B. (D) Viabilities of wild-type (WT) and Δ*npl4* expressing RTA grown on noninducing (glucose, left) and inducing (galactose, right) medium. (E) Expression of RTA and RTA~Δ~ was induced for 2 h in the presence and absence of cLβ-1. RTA variants were immunoprecipitated (IP) from cell extracts prepared in the presence of 10 mM *N*-ethyl maleimide. Proteins were identified by immunoblot (IB) for ubiquitin (left) and RTA variant (right). RbIgH, rabbit immunoglobulin heavy chain.](zmk0151095250005){#F5}

Npl4p is a Cdc48p cofactor that, along with its partner Ufd1p, recognizes polyubiquitylated ERAD substrates. RTA~Δ~ was partially stabilized in a Δ*npl4* strain, whereas native RTA was not ([Figure 5](#F5){ref-type="fig"}C). Furthermore, we saw no growth advantage in Δ*npl4* cells expressing native RTA ([Figure 5](#F5){ref-type="fig"}D). Thus in yeast, polyubiquitylation may not be important for the dislocation of native RTA, a view that is consistent with our earlier observations that the ubiquitin ligase activity of Hrd1p is not required for this protein and that RTA variants lacking lysyl residues still retrotranslocate and disappear ([Figure 3](#F3){ref-type="fig"}). It is further apparent that, although a tiny proportion of the native RTA can be trapped as monoubiquitylated g0 and g1 species in the presence of the proteasome inhibitor cLβ-l, polyubiquitylated intermediates cannot be detected ([Figure 5](#F5){ref-type="fig"}E). In contrast there *is* evidence of some polyubiquitylated RTA~Δ~ ([Figure 5](#F5){ref-type="fig"}E), findings that are compatible with the Cdc48 complex--mediated dislocation of this misfolded substrate observed here ([Figure 5](#F5){ref-type="fig"}, A and C) and previously ([@B39]).

The Proteasome Determines the Fate of the RTA Variants
------------------------------------------------------

Although efficient degradation of RTA~Δ~ requires the Png1p--Rad23p proteasomal receptor complex ([@B39]), deletion of *PNG1* or *RAD*23 did not confer growth advantage to cells expressing RTA ([Figure 2](#F2){ref-type="fig"}A). This suggests that the native toxin can evade this proteasomal receptor complex, pointing perhaps to different proteasomal interactions of RTA and RTA~Δ~. To investigate this, we examined the RTA variants in yeast carrying defined mutations ([@B55]) in the Walker motifs of the six AAA-ATPase Rpt subunits of the 19S proteasomal regulatory particle (RP).

Degradation of RTA~Δ~ showed a marked requirement for Rpt2p ATPase activity, but not for the ATPase activities of the other Rpt subunits ([Figure 6](#F6){ref-type="fig"}A). The glycosylated forms of RTA~Δ~ disappeared selectively over time, suggesting exposure to cytosolic peptide:*N*-glycanase (Png1p). Because Rpt2p allows access of proteasomal substrates to the axial core of the proteasome ([@B42]), where the proteolytic activities reside, this suggests that RTA~Δ~ is normally degraded by the proteasome. In support of this, the disappearance of RTA~Δ~ was significantly retarded after treatment of the drug-sensitive JN284 strain ([@B24]) with the proteasomal inhibitor clasto-lactacystin β-lactone ([Figure 6](#F6){ref-type="fig"}C). It was also stabilized in a *pre1-1* mutant ([Figure 6](#F6){ref-type="fig"}D) in which the core β4 catalytic subunit of the proteasome is defective ([@B33]).

![Native RTA avoids proteasomal degradation. Top panels, pulse-chase of RTA~Δ~ (A) and RTA (B) in WT (SUB62) and *rpt1-6* mutant strains. Bottom panels, overlapping error bars have been omitted for clarity. (C and D) Pulse-chase analysis of RTA~Δ~ and RTA from JN284 cells treated with DMSO (vehicle) or DMSO/lactone cLβ-1 (C) and pulse-chase analysis of CPY\*, RTA~Δ~, and RTA in a *pre1-1* proteasomal core mutant strain and corresponding WT (cl3-ABYS-86) (D). Bottom panels in C as in A and B.](zmk0151095250006){#F6}

By contrast, native RTA dislocates in a process involving the 19S proteasome cap protein Rpt4p ([Figure 6](#F6){ref-type="fig"}B), which can extract some ERAD substrates from the ER ([@B43]). However, it shows no obvious requirement for the other Rpt subunits, Ubr1p (the N-recognin E3 ligase associated with Rpt6p; [@B71]; [Figure 1](#F1){ref-type="fig"}A) or the proteasome core itself ([Figure 6](#F6){ref-type="fig"}, C and D). Native RTA was not selectively deglycosylated ([Figure 6](#F6){ref-type="fig"}B), consistent with our observation that a *PNG1* deletion had no discernable effect on the native protein ([Figure 2](#F2){ref-type="fig"}A). Finally, RTA degradation is independent of ubiquitylation because RTA and RTA(0K) exhibit identical kinetics of turnover in pulse-chase analyses ([Figure 3](#F3){ref-type="fig"}D). It remains unclear what protease or pathway removes the bulk of this protein in the cytosol. Nevertheless, it is evident that at least a fraction of dislocated RTA can recover ribosome-inactivating ability because growth is severely affected upon toxin expression in the ER ([Figure 2](#F2){ref-type="fig"}A).

DISCUSSION
==========

Through the use of a relatively small number of luminal ERAD substrates a map of ERAD-L components has emerged ([@B15]). Glycoprotein substrate recognition by these pathways is currently being unraveled by defining critical glycan structures in positions of the substrate where overall protein folding and stability can be monitored ([@B60]; [@B72]). However, it remains unclear how a common substrate that presents ERAD-detectable motifs in more than one location is handled. We have therefore studied the fate of a newly made native and misfolded toxin in order to highlight similarities and differences in their handling by ERAD constituents. Such a study also probes the requirements for the uncoupling that must occur before reactivation of native toxin in the cytosol. Our data reveal that the yeast ERAD system can discriminate between two subtly different forms of this substrate, showing that although the steps in preparation for retrotranslocation are generally similar, the downstream cytosolic stages are strikingly different ([Figure 7](#F7){ref-type="fig"}).

![Interactions of RTA with components of the ERAD pathway. RTA variants (1), require ongoing transport to and from the Golgi (2), before recognition by the Hrd1p--Hrd3p--Der1p membrane-bound dislocation complex (3). Their fates then differ. Although a proportion of RTA requires Rpt4p functions for cytosolic activation (4) (the rest being degraded in a nonproteasomal manner), RTA~Δ~ is directed to the proteasome core by the Cdc48p complex, the proteasomal receptor Rad23p--Png1p complex and the proteasomal cap component Rpt2p (5).](zmk0151095250007){#F7}

RTA inhibits yeast cell growth dramatically ([@B3]) through the catalyzed depurination of the sarcin-ricin domain of 26S rRNA that results in ribosome inactivation and the inhibition of protein synthesis ([@B23]). By monitoring survival of otherwise sensitive yeast cells, and/or by analyzing acquired biochemical stability of the toxin substrate, we tested a range of strains lacking or carrying defects in many known ERAD components. RTA was also expressed in a form that is unable to acquire its native structure, either before or after dislocation to the cytosol ([@B59]). The fate of this RTA~Δ~ was monitored by following its kinetics of degradation in selected strains of yeast.

For dislocation to the cytosol, both forms of RTA need ongoing traffic to the Golgi and they show a specific requirement for Erp2p, a protein of the p24 family that has a poorly understood role in bidirectional transport (cycling) between the ER and Golgi. Other Δ*erp* strains, including the *p24*Δ*8* that lacks all eight p24 genes ([@B64]), exhibit severe growth inhibition when expressing ER-targeted RTA. The p24 proteins are proposed to act as negative regulators of COPII vesicle entry for different substrates ([@B64]), where individual p24-COPII complexes preclude entry of specific cargoes into transport vesicles unless they display high affinity for budding components. It follows, however, that in the absence of all the members of this family, RTA would have unfettered access to budding vesicles and may recycle by default. A similar dependency on COPII-associated proteins has been reported for the Erv29p-dependent ER--Golgi transport of CPY\* ([@B30]), suggesting that it is the cycling of the substrate that is important. As with other examples of ERAD substrates that cycle at the ER--Golgi interface ([@B13]; [@B66]; [@B30]; [@B67]), RTA lacks a C-terminal HDEL sequence so the mechanism of retrieval remains unknown.

Both RTAs show a common requirement for the central Hrd1p--Hrd3p--Der1p ubiquitylation complex, supporting the view that the structurally native RTA can pose as an ERAD-L substrate. The requirement for Hrd1p reflects its structural role and is not related to canonical ubiquitylation because it is observed even with a catalytically inactive Hrd1p and when the native toxin lacks all internal lysyl residues. This lends further support to the idea that this Hrd1--Hrd3--Der1 complex may not only serve as a focal point for the recruitment of luminal and cytosolic ERAD components, but that it may constitute the core of a membrane-spanning retrotranslocon ([@B25]). The lesser requirement for the membrane anchor Cue1p suggests that a poorly ubiquitylated substrate like RTA might also dislocate through mobile, nonanchored Hrd1--Hrd3p complexes. RTA~Δ~ becomes more heavily glycosylated than RTA, presumably because in the more structurally defective toxin, the two *N*-glycan sequons have had prolonged exposure to oligosaccharyl transferase. For the weakly glycosylated native RTA, we observed no dependence on calnexin or on the intermediaries that extricate glycosylated substrates for passage to the E3 ligase complex (e.g., the mannosidase-like protein of the ER, Mnl1p). Furthermore, there is no clear role for the Yos9p lectin component of the Hrd1p complex either. It is known that the OS-9 mammalian ortholog of Yos9p can bind to both glycosylated and nonglycosylated ERAD substrates to deliver them to SEL1L (Hrd3p; [@B17]; [@B1]). OS-9 thereby acts as a kind of gatekeeper to the HRD1 complex in mammalian cells. In the absence of a role for Yos9p in the ERAD of RTA in yeast cells, it remains unclear precisely how this substrate is delivered to the central Hrd1p--Hrd3p complex. Furthermore, the ubiquitin ligase that monoubiquitylates RTA has not been identified and any role for Sec61p is also unresolved at this time.

After convergence at the Hrd1p--Hrd3p--Der1p complex, RTA then requires the 19S proteasome cap subunit Rpt4p that has been associated with extracting CPY\* from the ER membrane ([@B43]). However, this phase of the toxin ERAD process shows no obvious requirement for other Rpt subunits including Rpt2p (the base subunit of the cap that can open the proteolytic chamber; [@B42]) and does not involve Cdc48p, Ubr1p (an *N*-recognin E3 ligase associated with Rpt6p; [@B71]), or rather curiously, the proteasome core itself. The effect of *rpt4* on the ERAD of native RTA is probably not related to a general unfolded protein response (UPR) effect ([@B43]) because this defective RP subunit has a clear consequence on the ERAD of native RTA, but it has no effect on the ERAD of RTA~Δ~. It is not unreasonable therefore to speculate that in yeast, native RTA is dislocated without a polyubiquitin tag in a process facilitated by a specific base subunit of the proteasome cap.

In the disposal of RTA~Δ~, an essentially similar substrate save for a short internal deletion that renders it incapable of attaining correct native structure, there is a contrary and very noticeable involvement of Cdc48p, Npl4p, the Png1p--Rad23p proteasomal receptor complex, Rpt2p, and the proteasome core. Such a profile suggests that RTA~Δ~ behaves as a classical ERAD substrate, most likely extracted by the Cdc48 complex as a polyubiquitinated protein that is then deglycosylated in the cytosol by peptide:*N*-glycanase and degraded in the proteasome after gating interactions with Rpt2p.

The site or number of lesions that lead to recognition by ERAD components clearly influences downstream pathways. RTA presents as an ERAD-L substrate, most likely through structural alterations that involve interaction of a C-terminal hydrophobic patch in this protein with ER lipids ([@B46]). In a normal mammalian cellular intoxication this patch is occluded by RTB ([@B58]) until revealed by reduction of the holotoxin in the ER ([@B63]). However, after dislocation, native RTA is handled very differently to RTA~Δ~, which contains this same hydrophobic interface together with an internal lesion that affects its folding. We propose that engagement or otherwise with Cdc48p determines subsequent presentation of RTA to the proteasome, whereupon ATPase subunits of the proteasome RP discriminate between the two toxin forms. The ability of native RTA to evade the proteasome core and gain activity shows that the fate of a protein dislocated by Hrd1p-dependent processes is not necessarily destruction. We conclude that interactions with Cdc48p and the manner of toxin presentation to the proteasome RP permit an unexpected divergence in fate on the cytosolic face of the ER membrane that is distinct from the Doa10p scrutiny of cytosolic proteins ([@B48]).
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BFA

:   brefeldin A

cLβ-1

:   clasto-lactacystin β lactone

DMSO

:   dimethyl sulfoxide

ER

:   endoplasmic reticulum

ERAD

:   ER-associated protein degradation

RP

:   proteasome regulatory particle

RTA

:   ricin A chain

RTB

:   ricin B chain.
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